about
[Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyP67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD)[Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer].Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.Simple screening tools predict death and cardiovascular events in patients with rheumatic disease.[Rheumatoid symptoms in patients with hematologic neoplasms].Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases.RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition.Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.[Systemic sclerosis]Vaccination survey in patients with rheumatoid arthritis: a cross-sectional studyScreening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions[Systemic lupus erythematosus. A problem based approach][Rheumatic diseases with initial manifestations in middle age: gout, rheumatoid arthritis and ANCA-associated vasculitides][Cardiovascular comorbidity and its risk factors in rheumatoid arthritis][Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis]Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritisPrevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 PatientsCost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status
P50
Q31112566-C8C6650B-F005-4D5E-8B2A-DF9D19C08F83Q33984823-CD887489-D8F0-4746-BA10-877714E3CC0DQ34238532-FC34DD21-2067-4AEE-B97A-E6C4F1B26C51Q40965334-52401E59-4C62-4BEE-A9B5-A93B909FE4FDQ41026649-ACDFA945-DDD6-4E33-9092-4A4393C0E971Q41034755-4E4FF31C-6835-4D4A-AA0B-F9BC0BBCCB96Q48152632-9F413F2B-4DFF-45D3-A2E0-29E2E34CF516Q50057578-8F95E1F4-A411-4294-B1EB-0623CE55756DQ50231926-CCD53FED-FECE-4FDA-982E-8F674BCBAED1Q50962993-E5C28202-01D4-4004-A384-FE84C5EE5128Q52869895-A92E7614-20C0-4AC9-ACD6-210ABA9CA2D2Q80260010-3D564020-E4DA-4224-A7FE-357742ABFE23Q83425358-8EA2DF90-690B-4088-B45F-1B9B2E1F6541Q84131907-63D4723F-7055-4356-9B3F-535363B23D0EQ84566584-7A0B7FAA-25B2-41B5-87EA-A4BEFA468905Q84806400-B3256E4D-C70F-4816-BCB3-140794960CD1Q84815164-A1648C04-C5E0-4862-B248-108058C28587Q85589116-BC93BC81-D5E7-4A86-90ED-3208B1B2C525Q86641959-6E04CC2F-F715-4148-A560-7E540B4278BEQ89230692-8AEBB1FB-EF58-4CF9-8EBD-5B15052EB9CDQ90030598-00103201-CE6D-4B02-936A-295D9E1D13E9
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
S Kleinert
@en
S Kleinert
@nl
type
label
S Kleinert
@en
S Kleinert
@nl
prefLabel
S Kleinert
@en
S Kleinert
@nl
P31
P496
0000-0002-2588-7547